Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis

Lee, Jieun; Ahn, Sang Bong; Yim, Sun Young; Jun, Dae Won; Ko, Min Jung; Park, Dong Ah; Yoo, Jeong‐Ju

doi:10.1111/jvh.13679

Cited by 3 publications

(1 citation statement)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have demonstrated a strong association between liver stiffness values (LSV) and HCC development in the last decade. In particular, most of these studies were conducted after the advent of DAAs, a therapeutic regimen that represented a Copernican revolution in the treatment of HCV, also reaching a sustained virological response (SVR) > 95% in most complicated patients [ 50 , 51 , 52 ].…”

Section: Clinical Application Of Liver Stiffness Assessment For Hepat...mentioning

confidence: 99%

Liver Stiffness Values to Predict Occurrence and Recurrence of Hepatocellular Carcinoma

Stasi,

Brillanti

2024

Life

View full text Add to dashboard Cite

Globally, liver cancer is the third most frequent etiology of cancer death, with the rates of occurrence of both new cases and mortality estimated to increase. Given the availability of multiple treatments, interdisciplinary management of the patient is crucial. Moreover, the diagnostic assessment of patients with severe liver fibrosis is essential for the staging of HCC and liver cirrhosis and early diagnosis of HCC. In this context, non-invasive evaluation plays a critical role in identifying prognostic factors of clinical application for the surveillance of the occurrence or recurrence of HCC. The new frontiers of transient elastography have become a useful tool to assess the risk of HCC occurrence and recurrence. There has been a major increase in studies investigating the cutoff liver stiffness value that best predicts the need for monitoring for the onset of HCC. Therefore, this review discusses the new advances that have occurred in the last four years on HCC, highlighting the new frontiers of non-invasive evaluation of HCC subjects, with particular attention regarding the clinical application of liver stiffness assessment for de novo HCC and predicting recurrence in patients with chronic HCV achieving sustained virological response after treatment with direct antiviral agents.

show abstract

Section: Clinical Application Of Liver Stiffness Assessment For Hepat...mentioning

confidence: 99%

Liver Stiffness Values to Predict Occurrence and Recurrence of Hepatocellular Carcinoma

Stasi,

Brillanti

2024

Life

View full text Add to dashboard Cite

show abstract

The prevalence of hepatitis C virus genotypes and factors associated with cirrhosis, fatty liver, and viral load: A registry‐based cross‐sectional cohort study in Western Iran during 1999–2023

Sayad,

Bozorgomid,

Sayad

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

Background and AimsHepatitis C virus (HCV) is an important infectious disease that imposes a significant burden on healthcare systems. Determining the prevalence of HCV genotypes in a area is essential for the successful implementation of HCV elimination programs and allocation of financial resources to direct‐acting antiviral direct‐acting antivirals (DAA) treatments against prevalent HCV genotypes. Accordingly, we conducted a registry‐based cross‐sectional cohort study to investigate the prevalence of HCV genotypes and factors associated with cirrhosis, fatty liver, and viral load in Kermanshah Province, Western Iran.MethodsPatients presenting to the Hepatitis Clinic of the Research Center for Infectious Diseases affiliated with Kermanshah University of Medical Sciences between 1999 and 2023 were enrolled in this study. Serum samples were collected to assess HCV genotypes and viral load. Additionally, demographic data and the status of cirrhosis and fatty liver were extracted from the registry system records throughout the study period.ResultsRecords of 828 patients with an average age of 40.38 ± 11.72 years (range: 11–80 years) were included in the study that 721 individuals were male, and 107 were female. The prevalence of fatty liver and cirrhosis was 30.3% and 12.9%, respectively. Four genotypes (1, 2, 3, and 4) and four subtypes (1a, 1b, 3a, and 3b) were identified, with subtype 3a (55.7%) being the most prevalent, followed by subtype 1a (34.3%). None of the variables including age, gender, viral load level, and genotypes 1 and 3 were associated with fatty liver or cirrhosis. However, age, gender, and genotype were correlated with the viral load (p ≤ 0.05).ConclusionThe most common HCV subtypes in Kermanshah were 3a and 1a. Genotypes 2 and 4 were identified in one case each. Further studies on identifying HCV subtypes in different regions of the country are recommended to manage HCV infection and predict the prognosis.

show abstract

The Impact of the G6PD Gene Mutations in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Multicenter Observational Study

Smirne,

Crobu,

Gerevini

et al. 2024

Genes

View full text Add to dashboard Cite

Following the advent of direct-acting antivirals (DAAs), the treatment of hepatitis C virus (HCV) infection is now rarely challenging. However, data are still limited concerning DAA use in patients affected by glucose-6-phosphate dehydrogenase deficiency (G6PDd). Based on these considerations, the goal of this study was to evaluate the effectiveness and safety of DAAs in this subpopulation. A retrospective multicenter observational study (2015–2023) was conducted on all 2754 consecutive HCV-positive patients treated with first- and second-generation all-oral DAAs, and with a G6PDd diagnosis confirmed by quantitative testing (n = 38). At the treating clinician’s discretion, an enhanced clinical and laboratory follow-up was performed, generally on a monthly basis both during treatment and up to six months after the end of it. Concerning hematochemical parameters, no significant differences were found between any considered time point. In all cases, no treatment-related adverse events were reported, and virologic response rates were as expected without G6PDd. In conclusion, in a large experience which, to the best of our knowledge, is unprecedented in the literature, the treatment of HCV hepatitis with nearly all available DAAs in patients with G6PDd as a comorbidity—a common occurrence in countries such as Italy—proved to be highly effective and safe.

show abstract

Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis

Cited by 3 publications

References 117 publications

Liver Stiffness Values to Predict Occurrence and Recurrence of Hepatocellular Carcinoma

Liver Stiffness Values to Predict Occurrence and Recurrence of Hepatocellular Carcinoma

The prevalence of hepatitis C virus genotypes and factors associated with cirrhosis, fatty liver, and viral load: A registry‐based cross‐sectional cohort study in Western Iran during 1999–2023

The Impact of the G6PD Gene Mutations in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Multicenter Observational Study

Contact Info

Product

Resources

About